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respiratory product class. Using a dynamic price development graph, the model 
provides explanations for price changes at re-referencing time-points. The model 
clearly demonstrates that Greece leaving the EU will have a significant impact on 
price and revenue across markets, demonstrating the spill-over caused by interna-
tional referencing. ConClusions: The impact of Grexit goes well beyond Greece, 
directly affecting pharmaceutical price and revenue throughout Europe. PRISM 
can be used to assist manufacturers in developing a comprehensive pricing strat-
egy and facilitate dialog with governments operating within fiscally constrained 
environments. The model can also be used to test future scenarios as emerging 
markets are increasingly adopting reference pricing.
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objeCtives: This study sought to identify disease- and patient-specific charac-
teristics impacting on disease progression and outcomes, and to determine key 
attributes to be used in developing a conceptual model of multiple myeloma 
(MM). Methods: English language studies reporting MM attributes and their 
association with disease progression and outcomes were identified from Embase 
and Medline (2004–2014) and congress abstracts (2012–2014) in a systematic litera-
ture review (SLR). A second SLR of treatment guidelines, economic models, health 
technology reports and studies on the burden of MM was also used. An attribute 
was defined as a metric or characteristic of MM that plays a potential role in the 
disease process. These attributes can be explanatory (e.g. patient characteristics) or 
dependant (e.g. survival). Results: From both SLRs, 95 MM attributes were identi-
fied. These were grouped into disease characteristics (e.g. light chains, International 
Staging System [ISS] stage, bone marrow plasma cells, extramedullary disease, 
karyotypic abnormalities), genetic factors [e.g. t(4;14), del(13p), del(17p), hypodip-
loidy, hyperdiploidy], patient characteristics (e.g. age, serum lactate dehydrogenase, 
gender, Eastern Cooperative Oncology Group performance status, comorbidities), 
outcomes (e.g. overall survival), quality of life and symptoms (e.g. pain, fatigue, 
weakness, bone fractures, infection). Attributes were then categorised as explana-
tory or dependent variables. Age, serum lactate dehydrogenase, light chains and 
M protein were among the most common explanatory variables in the literature. 
The most commonly reported dependent variable was overall survival, followed by 
quality of life. None of the studies presented a comprehensive set of determinants of 
disease progression and outcomes. ConClusions: MM is a heterogeneous condi-
tion and it is not yet clear which attributes play a key role in determining disease 
progression and survival. The next step in developing the conceptual model for MM 
is to ask physicians to validate the potential attributes identified and to clarify the 
relationships between validated attributes.
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objeCtives: Treatment switching commonly occurs in the pivotal HTA evidence 
for advanced or metastatic cancer treatments submitted to reimbursement agen-
cies. Simple approaches, such as Intention-to-treat (ITT) analysis, have typically 
been applied to data with treatment switching, despite simulation studies showing 
these to drastically underestimate the underlying treatment effect. Therefore, before 
these studies are included in secondary analyses, the data must be re-analysed 
appropriately. When only summary data are available, individual patient level data 
can be reconstructed using a simulation approach. Given patients switch on disease 
progression, their progression time is assumed equivalent to their switch time. 
Simulating this effectively requires an illness-death modelling framework; the pro-
cess of which is the aim of this research. Methods: An example was used, where 
Kaplan-Meier curves for all three transition rates were available. The coordinates 
were extracted digitally from these scanned survival curves, and used to model 
the times for each transition. Many datasets were created, where the times for the 
transitions were simulated from the respective models. ITT summary statistics 
were calculated for each dataset; then averaged over. Examples with increasingly 
less information on which to estimate the transition rates were also systematically 
investigated. Results: When information on transition rates is available, the pro-
cess is easy to implement; giving data that are, on average, broadly representative 
of the original dataset with median survival times and overall survival hazard ratio 
differing by less than 10% and 0.05 respectively. As the information becomes more 
limited, the process requires additional assumptions, and ultimately may not be 
feasible. ConClusions: Using an illness-death modelling framework to simulate 
individual patient level data is affected by the information available to the analyst. 
However, this approach is important, when addressing treatment switching where 
only summary data are available, as the relationship between time to progression 
and overall survival is modelled correctly.
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objeCtives: Over the past five years, the prevalence and incidence of HIV in Russian 
Federation have increased dramatically. The application of global Markov models, 
and cost conditions applied in Italy, the use of DMF is economically sustainable 
for the NHS. Plausibly, the introduction and usage of this new therapy in RRMS 
patients will ensure clinical benefits for patients without resulting in additional 
costs for the NHS.
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objeCtives: Ministry of Health of Russian Federation announced the support of 
innovative development of pharmaceutical industry. In accordance with these plans, 
we aimed to develop a methodology for quantitative assessment of therapeutic 
value of innovative medical technologies in a multi-criteria decision analysis man-
ner. Methods: The questionnaire was developed during pilot survey (10 experts). 
Then 248 respondents assessed criteria significance (weights) of 14 features of an 
innovative drug and 7 features of a relevant disease. Also they estimated scale’s val-
ues. The respondents were medical practitioners and decision makers in healthcare. 
Results of the survey were analyzed using statistical methods. Results: The most 
valuable features are clinical efficacy and clinical safety with the weights of 9.77% 
and 9.08%, respectively. Absence of effective treatment of the disease, mortality and 
influence on quality of life also are among the valuable features with the weights 
of 8.08%, 7.72% and 7.47%, respectively. Minimal weights have new manufacturing 
technique of the drug (0.69%) and new drug formulation (0.03%). ConClusions: 
Significant and non-significant features of an innovative medical technology and 
disease for which it is intended in terms of therapeutic value were identified. We 
plan to optimize set of criteria and scales and then to assess reliability and validity 
of the developed instrument. This methodology being incorporated in the system 
of evaluation of medical technologies and combined with other methods of analy-
ses will help decision-making regarding innovative drugs in Russia become more 
harmonious and transparent.
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objeCtives: The cost-effectiveness of screening interventions is typically exam-
ined using simulation models. These permit comparisons of multiple screening 
strategies. Cost-effectiveness estimates from such models depend, in part, on what 
alternatives analysts choose to compare and how the simulation results are inter-
preted. Sometimes the comparisons and interpretations made are inappropriate, 
which can obscure evidence and lead to the wrong policy conclusions. The objective 
of this study is to explain eight simple steps that analysts can take to avoid these 
problems. Methods: We use examples from the literature to show how these 
problems can arise and to explain how they can be avoided. The examples chosen 
are from a recent systematic review of the cost-effectiveness of cervical screen-
ing. Results: The eight recommendations are: (i) report costs and effects, rather 
than just incremental cost-effectiveness ratios (ICERs); (ii) present a cost-effec-
tiveness plane; (iii) report cost and effects for all strategies, not just those on the 
efficient frontier; (iv) do not report ICERs for dominated strategies; (v) report costs 
and effects to sufficient significant figures; (vi) include all simulated strategies in 
the basecase analysis; (vii) do not report ICERs for strategies for which it is antici-
pated the inclusion of additional strategies would lead to significant changes in 
the estimated ratio; (viii) when there are multiple factors to vary in a screening 
programme, only vary these factors one at a time when creating alternative strat-
egies. ConClusions: The cost-effectiveness estimates from simulation models 
are particularly dependent on the choices taken by analysts regarding both the 
modelling of alternatives and the interpretation of the cost and effects estimates. 
Although the analytical flaws informing our recommendations might seem obvious, 
they occur with surprising frequency in the literature. The simple eight-item list 
presented here will support better use of screening models in identifying optimal 
policy choices.
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objeCtives: The possibility of Greece leaving the European Union (Grexit) is 
well-publicized, but its impact on the pharmaceutical industry has not been fully 
determined. Majority of established markets use pricing rules that reference 
products both across (international reference pricing; IRP) and within (thera-
peutic reference pricing; TRP) country-lines. IRP and TRP are used as effective 
measures to control price of pharmaceutical products. There is a growing need 
to understand how Grexit will impact these mechanisms through direct or indi-
rect means. Methods: Navigant’s Price and Revenue Impact Simulation Model 
(PRISM), which simulates the impact of IRP and TRP, as well as parallel trade and 
generic entry, was used to quantitatively assess the impact on drug prices across 
50 markets in the EU, North America, Latam, MENA-CIS and Asia. Respiratory 
products were analysed as a class to prevent a biased analysis towards particular 
pharmaceutical companies. Two potential scenarios were analysed with respect 
to Grexit: Markets referencing Greece switch referencing to Slovakia, a replace-
ment low-priced Euro currency Mandatory price cut in Greece resulting from a 
currency shift to the Greek Drachma Results: Outputs of the analysis include 
impact on price, revenue and net present value as well as parallel trade of the 
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objeCtives: The observational, non-interventional EDGE study showed that a DPP-4 
inhibitor, vildagliptin, is efficacious in patients with type 2 diabetes mellitus who 
have suboptimal glycaemic control on metformin monotherapy in the real-life set-
ting, confirming the results of previous randomised clinical trials. We sought to 
perform a health economic evaluation using using patient level data (PLD) from 
EDGE using an established diabetes outcomes model. Methods: The IMS Core 
Diabetes Model (CDM) was used to evaluate the lifetime costs and quality adjusted 
life expectancy (QALE) of two different regimens: metformin+vildagliptin compared 
to metformin+sulphonylurea (SU). Annual therapy costs were: £106.79 (year 1), then 
£110.51 (year 2+) for metformin+SU and £410.53 (year 1), then £412 (year 2+) for 
metformin+vildagliptin. Therapy escalation at HbA1c of 8.5% was modelled assum-
ing insulin glargine+metformin (cost £899.51 year 1; £806.84 year 2+). Published 
meta-analysis data were used for hypoglycaemia rates. Multivariate regression 
analysis of PLD output from CDM was undertaken using R version 2.15.2. UK costs 
(£GBP) and health benefits were discounted at 3.5%. Results: Mean discounted 
QALE was 11.01 years (SD 2.5). QALE decreased with increasing age (-0.19 per year, 
p< 0.001) and (-0.18 per year, p< 0.001) for metformin+SU and metformin+vildagliptin 
regimens, respectively. Increasing diabetes duration was associated with a greater 
decrease in QALE with metformin+SU (-0.18 per year, p< 0.001) compared to 
metformin+vildagliptin (-0.08 per year, p< 0.001). Each unit increase in baseline 
BMI was associated with a -0.12 decrease in QALE for metformin+SU (p< 0.001), 
with no significant difference observed in the metformin+vildagliptin regimen. 
After adjustment metformin+vildagliptin was associated with a £595.30 reduction 
in overall costs compared to metformin+SU. ConClusions: The statistical analy-
sis of PLD output provides a mechanism for identifying greatest potential health 
gains. Despite being positive in all patients, gains in QALE were greater in patients 
with longer diabetes duration and metformin+vildagliptin regimen compared with 
metformin+SU under a real-life setting.
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objeCtives: Surgery in cost-effectiveness analysis can lead to counter-intui-
tive results, with patients whose disease progresses faster undergoing surgery 
sooner. As surgery typically results in improved quality of life (QoL) following 
intervention surgery can have a beneficial impact on ICERs for less successful 
treatment, in spite of a patient preference to avoid surgery. This study under-
took a targeted review of previous NICE technology appraisals in order to assess 
the impact that surgery has had on decision making in the UK. Methods: 
A sample of NICE technology appraisals were reviewed to identify papers 
that have included surgery in their modelled clinical pathways. Key model 
inputs, results and the impact of surgery on model results were extracted for 
each study. Results: Two technology appraisals were identified that incor-
porated surgery as a clinical outcome. In TA297, surgery had minimal influ-
ence on model results. With both low incidence and no substantial impact of 
surgery on QoL. In TA329, utility values associated with surgery were 0.7 com-
pared with pre-surgery values ranging from 0.41 to 0.87. Immediate colectomy 
was found to dominate all non-surgical strategies. If immediate colectomy was 
excluded as a treatment option, no novel treatments would be cost-effective 
against conventional care in spite of this being the least effective treatment. 
Whilst a number of factors contribute to the overall result, the impact of surgery 
should be quantified. ConClusions: Surgery can have a counter intuitive influ-
ence on model results, with a negative event having a long-term positive impact 
on patient QoL. From this review a number of factors have been found to influence 
the magnitude of this impact. These include health state utilities before and after 
surgery, and timing of surgery. Decision rules are required that ensure that surgery 
is properly accounted for when making decisions, factoring in higher surgical rates 
into decision making may partly address this issue.
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objeCtives: The Timed Automata modeling paradigm has emerged from 
Computer Science as a mature tool for the functional analysis and performance 
evaluation of timed distributed systems. This study is a first exploration of the 
suitability of Timed Automata for health economic modeling, using a case study 
on personalized treatment for metastatic Castration Resistant Prostate Cancer 
(mCRPC). Methods: The treatment process has been modeled by creating several 
independent timed automata, where an automaton represents a patient, a physi-
cian, a test, or a treatment/testing guideline schedule. These automata interact 
via message passing and are fully parameterized with quantitative information. 
Messages can be passed, asynchronously, from one automaton to one or more 
other automata, at any point in time, thereby triggering events and decisions in the 
treatment process. In the automata time is continuous, and both QALYs and costs 
can be incorporated using (assignable) local clocks. Uncertainty can be modeled 
using probabilities and timing intervals that can be uniformly or exponentially 
distributed. Software for building timed automata is freely available for academic 
use and includes procedures for statistical model checking (SMC) to validate the 
(internal) behavior and results of the model. Results: In several days a Timed 
Automata model has been produced that is compositional, easy to understand 
and easy to update. The behavior and results of the model have been assessed 
using the SMC tool. Actual results for the mCRPC case study obtained from the 
Timed Automata model are compared with results of a Discrete Event Simulation 
model in a separate study. ConClusions: The Timed Automata paradigm can be 
successfully applied to evaluate the potential benefits of a personalized treatment 
process of mCRPC. The compositional nature of the resulting model provides a 
i.e. ARAMIS and CEPAC, for cost-effectiveness analysis in Russia is not possible due 
to differences in the disease classifications and lack of statistical data. The purpose 
of this work was the modeling of HIV progression in Russian HIV-infected popula-
tion. Methods: We develop the Markov model based on transitions through four 
mutually exclusive health states defined by CD4+ cell count ranges (> 500, 351–500, 
201–350, and < 200 cells/ml) and death and baseline characteristics of high prognostic 
value, such as viral load, age, sex, and antiretroviral treatment receiving. To iden-
tify the model’s parameters we used state statistics and publications of the Russian 
Federal Research Centre for Prevention and Control of AIDS. In order to validate 
model we calculated life expectancy after diagnosis using Monte-Carlo simulation 
of treated and non-treated cohorts. To study the influence of treatment on life expec-
tancy we used the 1st line regimen abacavir + zidovudine + lamivudine + enfuvir-
tide. Results: Life expectancy of treated patients is significantly higher compared 
to patients who did not receive treatment (medians and quartiles 24.6 [22.6; 26.5] 
and 13.8 years [12.7; 14.4] years, respectively, P< 0,001, Mann-Whitney U-test). These 
results acceptably correspond to the results of cohort studies and clinical trials. Life 
expectancy is significantly lower for men than for women both with and without 
treatment. ConClusions: The results of modeling conform the real data from the 
Russian population. The model is currently being finalized to calculate QALY, ICER, 
and others.
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objeCtives: Published ISPOR guidelines indicate that new economic models should 
be subjected to through internal testing and debugging. Moreover, evidence that this 
has been done should be provided. Currently there are few published examples 
of such internal validation work. The aim of the present analysis was to perform 
verification and validation analyses of a novel model for Type 1 Diabetes (the PRIME 
Diabetes Model). Methods: Source code (Java) for the T1D PRIME Diabetes Model 
was delivered to an independent third party. Program code was reviewed for syntax 
errors and tested via a separate software environment. This process included using 
null and extreme input values to test whether the expected outputs were produced. 
Replication tests using equivalent endpoint values were also performed. Verification 
queries were resolved by discussion and the findings of the analysis were described 
in a report. Results: Internal validation confirmed all numbers and formulas col-
lected from the literature and examined whether they were correctly implemented 
in the source code. Face validity was established with regard to the model’s struc-
ture, use of available clinical evidence, problem formulation and results. Given that 
the PRIME Diabetes Model is programmed in Java, MATLAB was used to validate 
model components independently and results were tested at patient mean levels 
as well as the corner cases of minimum and maximum values in order to ensure 
the model produced valid results over the entire range of patient characteristics. 
The model passed both internal and face and validity reviews. ConClusions: 
Published verification analyses in line with ISPOR guidance for all new health 
economic models would improve transparency and provide a valuable resource for 
health care decision makers. Using the PRIME Diabetes Model, the present analysis 
provides a real-world example of how verification and validation analyses can be 
performed and reported.
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objeCtives: The infant mortality rate is considered an important general indicator 
both of health conditions as the living conditions and development of a population. 
By presenting certain sensitivity to various external factors, this rate is directly related 
to economic and social characteristics. It’s understood that high infant mortality rates 
are associated with the needs of socioeconomic conditions. Thus, the factors influenc-
ing poverty levels (one-dimensional and multidimensional) on Infant Mortality Rate 
in Brazil are investigated in this paper. Methods: So it was considered, in addition 
to analyzing the impact of one-dimensional poverty, which measures poverty only by 
per capita income, the impact of multidimensional poverty, whose definition incor-
porates other dimensions, such as sanitation, housing, information, among others. In 
order to delineate the models, variables such as per capita income, the Gini index and 
education level were employed for the Brazilian states from 2001 to 2011. Four models 
were developed to analyze both individually and together impacts of the explanatory 
variables on the infant mortality rate. For this purpose, panel data was used on fixed 
and random effects. Results: The results showed that decrease the concentration 
of income and increased educational level, in that order, were the variables which 
most contributed to the reduction of infant mortality over the period considered. In 
all, the one-dimensional and multidimensional poverty rates contributed significantly 
to the reduction of infant mortality rate. However, the ratio of multidimensional 
poor impact showed a three times higher than the proportion of one-dimensional 
poor. ConClusions: The findings indicate that it is essential to the formulation of 
public policies to reduce income concentration allied to improvements in educational 
conditions, and reduction of multidimensional poverty rates in order to tackle the 
problems of poor health, and thus reduce the rate of infant mortality.
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